ipilimumab,nivolumab,cabozantinib
bms,exelixis
['lba8', 'cabozantinib', 'triplet,(-triplete)', 'nivolumab', 'ipilimumab', 'cosmic-313', 'rcc,(-irccs),(-srcc),(-urcc)', 'nivo', 'ipi/']
#esmo22 #lba8 ph3 #cosmic-313 of triplet cabozantinib+nivolumab+ipilimumab improved pfs (hr=0.73, p=0.013) compared to ipi/nivo in untreated mrcc at 1l, os pending. 
@Huntsmancancer fellow, @SYSU & @UofT alumnus, #stargazer, #aurora chaser